TP53 and cancer: Additionally, they demonstrated high-affinity binding to MDM2 (KD = 1.32 μM and 1.72 μM) and significantly downregulated BCL2 gene and protein expression in cancer cells, reinforcing their mechanism of inducing apoptosis through dual targeting of the p53 and BCL2 pathways.